Aerosmith Postpones All Tour Dates to 2024: Steven Tyler’s Vocal Injury ‘More Serious Than Initially Thought’

Aerosmith has pushed their 2023 tour to next year after Steven Tyler suffered an injury that led to “bleeding vocal cords,” and has now been revealed to be “more serious than initially thought.”

In a statement shared on social media, the band said Tyler’s doctor “he fractured his larynx which requires ongoing care,” adding that he is receiving the best medical treatment available “but given the nature of a fracture, he is being told patience is essential.”

More from Variety

After Tyler first sustained the vocal injury, six tour dates were rescheduled to 2024, starting in January and running through the end of February, with stops in Detroit, Chicago, Washington, D.C., Toronto, Raleigh and Cleveland. The band anticipated returning by Oct. 11 but that is no longer the case.

The band said new dates will be “announced as soon as we know more.” All previously purchased tickets will be honored at the new concerts, and refunds will also be available to those who can’t attend the unannounced new dates.

Tyler also issued a personal statement, writing: “I am heartbroken to not be out there with Aerosmith, my brothers and the incredible Black Crowes, rocking with the best fans in the world. I promise we will be back as soon as we can! – Love, Steven.”

Bruce Springsteen was also similarly forced to push back all of his September shows due to his struggling with peptic ulcer disease. Reps said that Springsteen is on the mend with ongoing treatment, and that all the dates for the tour — which originally were to wrap up in mid-December — were being postponed “out of to an abundance of caution.”

The only concerts Springsteen has on the lineup at the moment are a slate of makeup shows in Philadelphia next August, while Aerosmith fans will have to wait for further confirmation on the band’s return.

Best of Variety

Sign up for Variety’s Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

Click here to read the full article.